Health
FDA says Paxlovid is not linked to COVID-19 rebound
As the U.S. Food and Drug Administration’s independent advisers prepare to discuss the full approval of Pfizer’s COVID-19 antiviral, Paxlovid, agency experts said this week that clinical trial data shows that it is safe and effective for treatment of mild to moderate illness in high-risk adults.
Top Stories
Just the News Spotlight
Just News, No Noise
Trending
- Trapped by court case, Trump turns Big Apple into his political playground
- Afroman parodies his 'Because I Got High' to mock Hunter Biden
- You Vote: Do you approve of red state efforts to resist the new changes to Title IX?
- After harrowing escape, survivor of Oct. 7 Hamas attacks faces death threats and doxxing in US
- Kristi Noem faces bipartisan bashing for shooting her 'untrainable' 14-month-old dog